Orexo Restructures Leadership to Drive Pipeline and AmorphOX-Focused Growth

The latest update is out from Orexo AB ( (SE:ORX) ).

Orexo AB is reshaping its organization and management team following the divestment of Zubsolv in the U.S. market, sharpening its focus on advancing new development programs and its AmorphOX technology platform. The company aims to retain strong U.S. commercial insight while pivoting toward pipeline growth and strategic partnerships to support long‑term value creation.

As part of the changes, industry veteran Lisa Moore becomes Senior Vice President, Products and Portfolio Strategy, joining the management team to steer long‑term product vision and ensure development candidates align with customer needs and growth priorities. Long‑time Orexo US Inc. president Robert DeLuca will retire from his role after more than a decade leading the U.S. business and Zubsolv commercialization, but will stay on through May 2026 and then continue in an advisory capacity to support strategic projects and the transition of Zubsolv US to Dexcel Pharma USA.

The most recent analyst rating on (SE:ORX) stock is a Hold with a SEK27.00 price target. To see the full list of analyst forecasts on Orexo AB stock, see the SE:ORX Stock Forecast page.

More about Orexo AB

Orexo AB is a Swedish pharmaceutical company focused on treatments for severe diseases and life‑saving rescue medications, leveraging its proprietary AmorphOX drug delivery technology to improve bioavailability and stability for both large and small molecules. With more than 30 years of experience and several globally approved drugs, the Uppsala‑based firm is advancing a diversified clinical and preclinical pipeline in partnership with external research, development, and commercialization collaborators, and is listed on Nasdaq Stockholm with ADRs trading on the U.S. OTCQX market.

Average Trading Volume: 76,339

Technical Sentiment Signal: Hold

Current Market Cap: SEK912.7M

See more insights into ORX stock on TipRanks’ Stock Analysis page.